Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety, Tolerability and Pharmacokinetics of TESP-0401 in Healthy Participants
NCT07658638Phase 1Recruiting
- Sponsor
- Tes Pharma
- Start
- Jul 2026
- Primary completion
- Mar 2027
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of TESP-0401 (20 cohorts), sponsored by Tes Pharma. Primary endpoint: Number of participants with SAEs, TEAEs, abnormal clinical laboratory tests results, abnormal vital signs, abnormal ECG readings and abnormal physical examination findings. Started Jul 2026; status: recruiting.
02
Drugs
TESP-0401
Beyond the preview
Go deeper on NCT07658638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07658638.